Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

913
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
913
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants

2.2K

Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.2K
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

5.7K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
5.7K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

815
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
815
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

2.4K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
2.4K
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

787
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
787

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Voacangine/coronaridine hydroxylases catalyze C19-hydroxylation in iboga alkaloid synthesis.

Planta·2026
Same author

Evolution of CYP71D drives the diversification of monoterpene indole alkaloid biosynthesis in Gentianales.

Plant communications·2025
Same author

Experimental and Computational NMR Studies of Large Alkaloids Exemplified With Vindoline Trimer: Advantages and Limitations.

Magnetic resonance in chemistry : MRC·2025
Same author

Structure and Synthesis of Vindolicine and Derivatives.

Chemistry & biodiversity·2024
Same author

Meroterpenoids? A historical and critical review of this biogenetic determinant.

Natural product reports·2023
Same author

Traditional Chinese medicine: saponins, critical micellar concentrations and partition coefficients.

Phytochemical analysis : PCA·2023

Related Experiment Videos

The Iboga Alkaloids.

Catherine Lavaud1, Georges Massiot2

  • 1Faculty of Pharmacy, Université de Reims Champagne-Ardenne, Institut de Chimie Moléculaire de Reims, UMR CNRS 7312, Case postale 44, UFR des Sciences Exactes et Naturelles, BP 1039, 51687, Reims, Cedex 2, France. catherine.lavaud@univ-reims.fr.

Progress in the Chemistry of Organic Natural Products
|February 15, 2017
PubMed
Summary
This summary is machine-generated.

Iboga alkaloids, found in Tabernanthe iboga, show promise for treating addiction. Ibogaine and 18-methoxycoronaridine are key compounds, with ongoing research into their synthesis and biological properties.

Keywords:
BiosynthesisCytotoxicityDrug cessation treatmentIboga alkaloidsLeishmaniasisStructural elucidationSynthesis

Related Experiment Videos

Area of Science:

  • Natural Products Chemistry
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Iboga alkaloids are indolomonoterpenes derived from the Tabernanthe iboga plant.
  • Ibogaine, a primary iboga alkaloid, possesses well-documented psychoactive properties and therapeutic potential for substance use disorders.
  • Challenges in ibogaine's legal status have spurred research into related compounds like 18-methoxycoronaridine.

Purpose of the Study:

  • To provide a comprehensive overview of iboga alkaloids.
  • To update current knowledge on their biosynthesis, discovery, and chemical characterization.
  • To review recent advancements in their synthesis and biological activities.

Main Methods:

  • Literature review and synthesis of existing research on iboga alkaloids.
  • Discussion of analytical techniques for alkaloid identification and structure elucidation.
  • Analysis of progress in chemical synthesis and biological evaluation.

Main Results:

  • Biosynthesis of iboga alkaloids remains incompletely understood.
  • New monomeric and dimeric alkaloids are continually being discovered.
  • Synthesis and biological evaluation of ibogaine and 18-methoxycoronaridine are advancing.

Conclusions:

  • Iboga alkaloids, particularly ibogaine and 18-methoxycoronaridine, hold significant therapeutic potential.
  • Further research into synthesis and biological mechanisms is crucial for their development.
  • Advancements in analytical and synthetic chemistry are key to unlocking their full potential.